These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 8298974)

  • 1. Sigma binding parameters in developing rats predict behavioral efficacy of a sigma ligand.
    Hemstreet MK; Matsumoto RR; Bowen WD; Walker JM
    Brain Res; 1993 Nov; 627(2):291-8. PubMed ID: 8298974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between modulation of the cerebellorubrospinal system in the in vitro turtle brain and changes in motor behavior in rats: effects of novel sigma ligands.
    Matsumoto RR; Bowen WD; de Costa BR; Houk JC
    Brain Res Bull; 1999 Mar; 48(5):497-508. PubMed ID: 10372510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism.
    Matsumoto RR; Bowen WD; Tom MA; Vo VN; Truong DD; De Costa BR
    Eur J Pharmacol; 1995 Jul; 280(3):301-10. PubMed ID: 8566098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug specificity of pharmacological dystonia.
    Matsumoto RR; Hemstreet MK; Lai NL; Thurkauf A; De Costa BR; Rice KC; Hellewell SB; Bowen WD; Walker JM
    Pharmacol Biochem Behav; 1990 May; 36(1):151-5. PubMed ID: 2161543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-related differences in the sensitivity of rats to a selective sigma ligand.
    Matsumoto RR; Bowen WD; Walker JM
    Brain Res; 1989 Dec; 504(1):145-8. PubMed ID: 2557123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible involvement of a sigma receptor subtype in the neck dystonia in rats.
    Nakazawa M; Kobayashi T; Matsuno K; Mita S
    Pharmacol Biochem Behav; 1999 Jan; 62(1):123-6. PubMed ID: 9972854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissociation of the motor effects of (+)-pentazocine from binding to sigma 1 sites.
    Matsumoto RR; Bowen WD; Walker JM; Patrick SL; Zambon AC; Vo VN; Truong DD; De Costa BR; Rice KC
    Eur J Pharmacol; 1996 Apr; 301(1-3):31-40. PubMed ID: 8773444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BMY-14802 reversed the sigma receptor agonist-induced neck dystonia in rats.
    Okumura K; Ujike H; Akiyama K; Kuroda S
    J Neural Transm (Vienna); 1996; 103(10):1153-61. PubMed ID: 9013402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential solubilization of rat liver sigma 1 and sigma 2 receptors: retention of sigma 2 sites in particulate fractions.
    Torrence-Campbell C; Bowen WD
    Eur J Pharmacol; 1996 May; 304(1-3):201-10. PubMed ID: 8813603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [3H]YM-09151-2 (nemonapride), a potent radioligand for both sigma 1 and sigma 2 receptor subtypes.
    Ujike H; Akiyama K; Kuroda S
    Neuroreport; 1996 Apr; 7(5):1057-61. PubMed ID: 8804051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological evidence for the involvement of sigma sites in DTG-induced contralateral circling in rats.
    Bastianetto S; Perrault G; Sanger DJ
    Neuropharmacology; 1995 Jan; 34(1):107-14. PubMed ID: 7623959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The functional sensitisation of sigma receptors following chronic selective serotonin reuptake inhibitor treatment.
    Faherty CJ; Harkin AJ; Leonard BE
    Eur J Pharmacol; 1998 Apr; 346(1):15-21. PubMed ID: 9617747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sigma-1 and sigma-2 sites in rat brain: comparison of regional, ontogenetic, and subcellular patterns.
    McCann DJ; Weissman AD; Su TP
    Synapse; 1994 Jul; 17(3):182-9. PubMed ID: 7974201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrimination of (+)-3-PPP sites from DTG sites by FH-510, a novel potent sigma ligand, in rat brain.
    Chaki S; Tanaka M; Muramatsu M; Otomo S
    Eur J Pharmacol; 1993 Nov; 250(1):173-5. PubMed ID: 7907020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacology of the novel and selective sigma ligand, PD 144418.
    Akunne HC; Whetzel SZ; Wiley JN; Corbin AE; Ninteman FW; Tecle H; Pei Y; Pugsley TA; Heffner TG
    Neuropharmacology; 1997 Jan; 36(1):51-62. PubMed ID: 9144641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional variation in the ratio of sigma 1 to sigma 2 binding in rat brain.
    Leitner ML; Hohmann AG; Patrick SL; Walker JM
    Eur J Pharmacol; 1994 Jun; 259(1):65-9. PubMed ID: 7957595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iontophoretic effects of sigma ligands on rubral neurons in the rat.
    Matsumoto RR; Walker JM
    Brain Res Bull; 1992; 29(3-4):419-25. PubMed ID: 1356600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 1,3-di-o-tolylguanidine (DTG), a sigma ligand, on local cerebral glucose utilization in rat brain.
    Hohmann AG; Matsumoto RR; Hemstreet MK; Patrick SL; Margulies JE; Hammer RP; Walker JM
    Brain Res; 1992 Oct; 593(2):265-73. PubMed ID: 1450934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kappa opioid receptor agonists inhibit sigma-1 (sigma 1) receptor binding in guinea-pig brain, liver and spleen: autoradiographical evidence.
    Brent PJ
    Brain Res; 1996 Jul; 725(2):155-65. PubMed ID: 8836521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo characterisation of [3H]ANSTO-14 binding to the sigma 1 binding sites.
    Nguyen VH; Mardon K; Kassiou M; Christie MD
    Nucl Med Biol; 1999 Feb; 26(2):209-15. PubMed ID: 10100221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.